Entrectinib: FDA Approved for NTRK-Fusion Positive Cancer

Entrectinib (Rozlytrek™, Genentech, Inc.) has just been FDA approved for use as treatment for patients with cancers containing neurotrophic tyrosine receptor kinase (NTRK) gene fusion, which is a genetic defect. This drug is to be used if there are no other effective treatments available. This approval marks the third time the FDA has approved a cancer drug based on a biomarker instead of tumor type. These types of approvals are beginning a paradigm in the development of cancer treatments for "t...
Continue reading

ROS1+ Non-Small Cell Lung Cancer: Entrectinib Shows Promise

Results have been strong for phase 1 and 2 clinical trials of entrectinib (RXDX-101), an orally available selective tyrosine kinase inhibitor, in treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). A ROS1 rearrangement is a chromosomal abnormality where ROS1 has mutated so that it signals cells to continuously survive and multiply, thereby causing cancer. ROS1-positive NSCLC is a distinct molecular subset of NSCLC that occurs in 1% to 2% of lung cancer cases. Compared wi...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.